Catalent, Inc. Announces First Quarter Fiscal Year 2021 Earnings Conference Webcast
Catalent, Inc. (NYSE: CTLT) will release its financial results for Q1 fiscal year 2021, ended September 30, 2020, on November 3, 2020, before the market opens. A management webcast is scheduled for 8:15 a.m. ET the same day to discuss these results. Access to the webcast and a supplemental slide presentation will be available through the company's website. Catalent is recognized for its advanced delivery technologies and has generated over $3 billion in annual revenue, employing approximately 14,000 people across 45 facilities.
- Strong market position as a leading provider in drug and biologics manufacturing.
- Generated over $3 billion in revenue in fiscal 2020.
- Extensive workforce of approximately 14,000 employees, including 2,400 scientists.
- None.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2021 ended September 30, 2020, before the market open on Tuesday, November 3, 2020. The Company’s management will host a webcast to discuss the results at 8:15 a.m. ET on the same day.
Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com.
A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.
The webcast replay, along with the supplemental slides, will be available for 90 days in the “Investors” section at www.catalent.com.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists, at more than 45 facilities and in fiscal 2020 generated over
More products. Better treatments. Reliably supplied.™
